ArticleThe oncologist2019

FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.

Nicholas C Richardson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.